Evgen Pharma Plc Placing for use after final read-outs of two Phase II clinical trials

Commenting on the Placing, Steve Franklin, CEO of Evgen Pharma, said:

“We are very pleased to have raised these additional funds from new and existing shareholders. The funds provide Evgen with additional working capital for use following announcement of the final read-outs of our two Phase II clinical trials, which represent significant value inflection points for the Company.”

Evgen Pharma Plc (LON: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions,today announced it has raised £0.75 million (before expenses) via a placing of 5,555,558 new ordinary shares of 0.25p each in the Company at a price of 13.5p per ordinary share.

The net proceeds of the Placing will be used by the Company to provide working capital for the months following read-outs from the Company’s two on-going Phase II trials in subarachnoid haemorrhage and metastatic breast cancer.

An application has been made for the Placing Shares to be admitted to trading on AIM which is expected to occur at 8.00 a.m. on 22 October 2018.

Total Voting Rights

Following Admission the Company’s issued share capital will comprise 98,912,416 ordinary shares with voting rights. The figure of 98,912,416 ordinary shares may therefore be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA’s Disclosure and Transparency Rules.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Evgen Pharma Plc

    More articles like this

    Evgen Pharma Plc

    21 Health Benefits of Broccoli

    Are you looking for a vegetable to spice up your diet in a healthy way? If yes, then broccoli, also called Brassica oleracea italica, is the vegetable you want. The dark green crucifer is not only

    Evgen Pharma Plc

    12 things that are actually tied to breast cancer

    According to the Centres for Disease Control and Prevention (CDC), breast cancer is the most common cancer in women. In the US, one in eight women will develop breast cancer during her lifetime. Those statistics sound

    Evgen Pharma Plc

    10 subtle signs of breast cancer

    A diagnosis of breast cancer can be terrifying. According to the CDC, Breast cancer is the most common cancer in American women of any race or ethnicity. Though the statistics might be scary, catching breast cancer

    Evgen Pharma Plc

    Evgen Pharma plc Investor Presentation in Manchester

    Evgen Pharma plc (LON: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that Steve Franklin, the Company’s CEO, will be presenting tomorrow evening at a ShareSoc Growth

    Evgen Pharma Plc

    ‘I never knew men could get breast cancer’

    Moses Musonga never thought men could get breast cancer until he was diagnosed with the disease in 2013. The 67-year-old Kenyan told the BBC that he was profoundly shock when doctors told him in 2013 that

    Evgen Pharma Plc

    Male Breast cancer:What are the signs and how to check?

    Breast cancer is more commonly associated with women more than with men, affecting approximately one in eight women in their lifetimes. However, men can still be diagnosed with breast cancer, albeit in far rarer circumstances. While